Ozempic lawsuit alleges diabetes, weight loss drugs cause serious gastrointestinal side effects

A Louisiana woman who was diagnosed with severe gastrointestinal problems after taking the weight loss and diabetes medications Ozempic and Mounjaro has filed a lawsuit against the manufacturers of the drugs.

Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are part of a class of drugs known as GLP-1 receptor agonists. While these medications were originally developed to treat patients with type 2 diabetes, in recent years, both drugs have been increasingly prescribed to help patients with obesity or who are overweight with weight loss and weight control.

Lawsuit Alleges Ozempic, Mounjaro Linked to Gastrointestinal Problems

According to her lawsuit, Jaclyn Bjorklund was prescribed Ozempic by her doctor to treat type 2 diabetes symptoms. In July 2023, she began taking Mounjaro.

After months of taking the two medications, Bjorklund alleges that she began to develop serious gastrointestinal problems, including vomiting and stomach pain. She says that she was hospitalized as a result of her stomach condition, and was forced to begin taking medications in order to relieve her gastrointestinal issues.

Bjorklund’s lawsuit alleges that the manufacturers of Ozempic and Mounjaro, Novo Nordisk and Eli Lilly, failed to properly warn patients about the risk of gastrointestinal problems that they could face from taking these medications.

The lawsuit alleges that the two drugmakers knew about the link between GLP-1 receptor agonists like Ozempic and Mounjaro and the increased risk of gastroparesis and other gastrointestinal conditions, but failed to share this information with doctors and patients.

Warnings About Gastrointestinal Side Effects With Ozempic

As the popularity of Ozempic and similar medications for weight loss and weight control has increased, doctors and patients have begun warning about the risk of gastrointestinal problems associated with these drugs.

One of the most serious conditions linked to the use of diabetes drugs like Ozempic is gastroparesis, a chronic condition in which the nerves and muscles in the stomach become weakened. As a result, patients with gastroparesis may experience other gastrointestinal side effects, including nausea and diarrhea.

Patients who have been prescribed Ozempic, Mounjaro, or other GLP-1 receptor agonists – including Rybelsus (semiglutide), Saxenda (liraglutide), Trulicity (dulaglutide), and Wegovy (semaglutide) – for diabetes or weight loss may be at risk of developing gastroparesis or other serious stomach issues.

Some of the other gastrointestinal conditions that have been linked to the use of these medications include bowel obstructions, ileus (the inability of the intestines to eliminate food or waste), intestinal blockages, and stomach paralysis, also known as “frozen stomach”.

Contact Our Law Firm to Start Your Claim Today

If you or a loved one were prescribed Ozempic, Wegovy, or similar diabetes and weight loss drugs and have been diagnosed with gastroparesis or other gastrointestinal conditions that are linked to these medications, you may be eligible to file a lawsuit and receive compensation.

To start the process of filing your claim today, contact the lawyers at Hissey Mulderig & Friend by calling our office toll-free at 1-866-806-8117, or by filling our our free claims submission form located on the right side of this page.

About the Author: Hissey, Mulderig & Friend